© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Suicide Rates Increasing among US Preteens, Particularly among Girls, Black and Hispanic Youth
August 13, 2024
Following a decrease, suicide rates among US preteens increased annually by 8.2% from 2008 to 2022, according to a recent cross-sectional study.
Shifting Trends in GLP-1RA Prescriptions: Daily Dose
August 13, 2024
Your daily dose of the clinical news you may have missed.
Blood Test Used to Detect Alzheimer Disease Improves Diagnosis Among Primary Care Clinicians: Daily Dose
August 12, 2024
Your daily dose of the clinical news you may have missed.
High-Intensity Interval Training May Improve Cardiorespiratory Fitness After Stroke
August 09, 2024
Findings from a new study suggest high-intensity interval training may be more effective in improving individuals’ cardiorespiratory fitness poststroke than moderate-intensity continuous training.
Long COVID Risk Declined Over the Pandemic: Daily Dose
August 09, 2024
Your daily dose of the clinical news you may have missed.
Visit to Primary Care Soon After Cancer Surgery Associated with Reduced Mortality Risk in Older Adults
August 08, 2024
In a new study of older adults who underwent cancer surgery, those who visited their PCP within 90 days had a significantly lower postoperative mortality rate.
Roflumilast Cream 0.15% Approved for Treatment of Atopic Dermatitis in Adults, Children: Daily Dose
August 08, 2024
Your daily dose of the clinical news you may have missed.
FDA Approves First Blood Test for Primary Screening of Colorectal Cancer
August 07, 2024
The Shield blood test is approved for primary CRC screening in adults 45 years and older at average risk for the disease.
Intervention Cuts Alcohol Use in Youths with Chronic Medical Conditions: Daily Dose
August 07, 2024
Your daily dose of the clinical news you may have missed.
Bayer Submits NDA to FDA for Elinzanetant for Treatment of VMS
August 06, 2024
The submission is based on data from OASIS trials that showed elinzanetant significantly reduced the frequency and severity of moderate-to-severe VMS associated with menopause.